Zhong Ji Longevity Science Group (HKG:0767) said it has agreed to dissolve three joint ventures in mainland China amid shifting market conditions, according to a Hong Kong bourse filing released Wednesday.
Shares of the company soared 12% in Thursday morning trade.
The three joint ventures set up between February and November 2024 aimed to explore biomedical trading, chronic disease treatment technologies, and longevity health services.
All were either non-operational or have ceased operations, the company said, adding that the dissolutions were mutually agreed upon with counterparties and would not materially impact its financials.
In a separate disclosure, the group said its unit Zhongli (Hainan) Life Science Technology on July 2 signed a deal with Beijing Sanyouli Heze Biotechnology to jointly advance a dental pulp stem cell injection therapy for periodontitis in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China.
Zhongli will act as the designated promoter of the therapy, handling publicity, commercialization, and global market expansion alongside Beijing Sanyouli and its partners.
Beijing Sanyouli, which specializes in stem cell R&D, has completed Phase I clinical trials of the treatment, according to the filing.
Zhong Ji said the collaboration aligns with its goal of building a life sciences platform and expanding in longevity diagnostics and health services.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。